A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer Read more
Impact of Bendamustine as an Alternative Lymphodepletion Regimen on Chimeric Antigen Receptor T-Cell Therapy Outcomes Read more
A Phase II Parallel Arm Study of Sacituzumab Govitecan-hziy in Patients with Advanced Thymoma and Thymic Carcinoma Read more
This protocol is for the use of CliniMACS CD34 Reagent System in a single patient with relapsed AML. Patient received salvage chemo and planned stem cell boost for cytopenias. Since donor is a haplo, plan is to give CD34 selected cells with some t cell add back. Read more
A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd), A B7-H3 ANTIBODY-DRUG CONJUGATE (ADC), IN COMBINATION WITH ATEZOLIZUMAB WITH OR WITHOUT CARBOPLATIN AS FIRST-LINE INDUCTION OR MAINTENANCE, IN SUBJECTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) Read more
Identification of Novel Metabolomics and MRI Based Biomarkers Predictive of Early Radiation Induced Cardiac Toxicity Following Treatment for Thoracic Malignancies Read more
Phase III randomized and double-blinded trial of de-escalated radiation in FMISO PET-selected good risk versus standard of care radiation in unselected HPV positive oropharyngeal cancer Read more
Determining the proportion of Cancer Center patients with certain diagnoses over the last two years who would be eligible for treatment with RefleXion Scintix technology. Read more
